Enveric Biosciences Discusses Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward in New Video Interview on SNN Network

Rhea-AI Summary

Enveric Biosciences (NASDAQ:ENVB), a biotechnology firm focused on cannabinoid medicines for cancer patients, discussed its recent acquisition of an exclusive license from Diverse Biotech in a video interview with CEO David Johnson. This strategic move aims to develop new treatments for conditions like radiodermatitis and chemotherapy-induced neuropathy. Enveric is dedicated to improving patient quality of life through rigorously tested innovations. The company continues to highlight its commitment to the cancer patient community through these advancements.

Positive

• Acquisition of exclusive license from Diverse Biotech to enhance product offerings.
• Focus on cannabinoid medicines aimed at improving life quality for cancer patients.
• Potential to address severe side effects from cancer treatments.

Negative

• None.

LOS ANGELES, CA / ACCESSWIRE / March 17, 2021 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with David Johnson, Chairman, and CEO of Enveric Biosciences (NASDAQ:ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, according to the company's website (see here: www.enveric.com).

Click the following link to watch the Video Interview:

Enveric Biosciences on Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward

You can follow SNN Network on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE

Please review important disclosures on our website at http://stocknewsnow.com/legal.php#disclaimer

About Enveric Biosciences

Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit https://www.enveric.com/.

About SNN Network

SNN Network is an investor portal covering the Small-, Micro- and Nano-cap markets by providing news, insights, education tools, and expert commentary. Subscribe now to our YouTube Channel to be notified when new CEO video interviews, Wall Street Views with investing experts, and Planet MicroCap Podcast episodes are available.

Subscribe NOW to SNN Network: http://bit.ly/1Q5Yfym

CONTACT:
SNN Network
info@snnwire.com

SOURCE: Enveric Biosciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/636051/Enveric-Biosciences-Discusses-Acquisition-of-Exclusive-License-from-Diverse-Biotech-and-Value-Catalysts-Moving-Forward-in-New-Video-Interview-on-SNN-Network

FAQ

What is the significance of Enveric Biosciences' acquisition of the exclusive license from Diverse Biotech?

The acquisition allows Enveric to expand its therapeutic portfolio, specifically targeting cancer treatment side effects, which could enhance its market position.

What conditions does Enveric Biosciences aim to address with its new cannabinoid medicines?

Enveric aims to develop treatments for radiodermatitis and chemotherapy-induced neuropathy, which are common side effects faced by cancer patients.

How does the acquisition affect Enveric Biosciences' growth potential?

The acquisition could position Enveric for significant growth by offering innovative solutions to unmet medical needs in cancer care.

When was the video interview regarding the acquisition published?

The video interview was published on March 17, 2021.